Christopher F Barnett, MD
Cardiovascular Disease (Cardiology) · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 3
- Since medical school
- 25 years
- Northwestern University Feinberg Medical School, 2001
Offices
3 locations · University of California San Francisco · Regents of the University of California
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Barnett’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A99520 · Current
Licensed to practise in California · since 2007 · expires 2028-11-30 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Advanced Heart Failure and Transplant
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Critical Care Medicine
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$65,679
Medicare paid this office $65,679 for 163 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 98 | $45,862 | $183 |
| Critical care, each additional 30 minutes | 35 | $7,502 | $91 |
| Long return visit (40+ min) | 22 | $4,609 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,000 | $105 |
| Insertion of artery tube for blood sampling or infusion through skin | 11 | $482 | $37 |
See all 6 services
| Critical care, first 30-74 minutes | 98 | $45,862 | $183 |
| Critical care, each additional 30 minutes | 35 | $7,502 | $91 |
| Long return visit (40+ min) | 22 | $4,609 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,000 | $105 |
| Insertion of artery tube for blood sampling or infusion through skin | 11 | $482 | $37 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 16 | $326 | $15 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 17 | 15 | – | 14 | – | – |
| Insertion of artery tube for blood sampling or infusion through skin | 12 | – | – | – | – | 13 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
163 Original Medicare patients in 2024. Average age 70 · Under 65 23% · 85 and older 13% · Women 46% · Also on Medicaid 57% · Health risk score 3.56. Sicker patients than 9 in 10 peers; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Heart failure 75% · Coronary heart disease 68% · Chronic kidney disease 68% · Diabetes 59% · Atrial fibrillation 49% · COPD 31% · Depression 29% · Stroke 26% · Dementia 21% · Cancer 15%.
The office billed $530,299, Medicare allowed $82,721 and paid $65,679; for 473 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 163 | 473 | 70 | 3.56 | $530,299 | $65,679 |
| 2023 | 177 | 699 | 71 | 2.71 | $865,081 | $107,645 |
| 2022 | 132 | 437 | 72 | 3.05 | $479,689 | $60,977 |
| 2021 | 214 | 529 | 71 | 2.72 | $392,381 | $87,636 |
| 2020 | 416 | 921 | 72 | 3.31 | $395,812 | $122,823 |
| 2019 | 873 | 1,569 | 72 | 2.91 | $434,687 | $139,299 |
| 2018 | 541 | 1,160 | 72 | 3.07 | $504,943 | $169,576 |
| 2017 | 442 | 958 | 72 | 3.02 | $428,229 | $136,845 |
| 2016 | 157 | 323 | 72 | 2.47 | $157,183 | $54,137 |
| 2015 | 16 | 20 | 66 | 2.68 | $4,558 | $906 |
| 2014 | 186 | 298 | 67 | 2.18 | $112,407 | $21,376 |
| 2013 | 454 | 753 | 70 | 1.94 | $261,015 | $48,155 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Critical care, first 30-74 minutes | 115 | $82,426 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $6,539 | $105 |
| Long return visit (40+ min) | 25 | $5,597 | $124 |
| Critical care, each additional 30 minutes | 26 | $5,294 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,845 | $154 |
2022: 6 services
| Critical care, first 30-74 minutes | 74 | $39,923 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $8,195 | $90 |
| Critical care, each additional 30 minutes | 16 | $3,480 | $94 |
| New patient visit (60+ min) | 12 | $1,956 | $163 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,220 | $87 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $1,019 | $73 |
2021: 4 services
| Critical care, first 30-74 minutes | 135 | $66,824 | $193 |
| Long return visit (40+ min) | 54 | $9,853 | $120 |
| Long return visit (40+ min) | 11 | $2,342 | $167 |
| New patient visit (60+ min) | 11 | $1,692 | $154 |
2020: 9 services
| Critical care, first 30-74 minutes | 202 | $93,010 | $194 |
| Long return visit (40+ min) | 72 | $11,602 | $96 |
| New patient visit (60+ min) | 19 | $2,770 | $146 |
| Dialysis procedure including 1 evaluation | 12 | $1,943 | $78 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $1,841 | $68 |
| Long return visit (40+ min) | 11 | $1,651 | $118 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 15 | $1,136 | $76 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 124 | $1,085 | $7 |
| Critical care, each additional 30 minutes | 11 | $1,041 | $95 |
2019: 8 services
| Critical care, first 30-74 minutes | 249 | $104,888 | $190 |
| Long return visit (40+ min) | 75 | $13,403 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 583 | $5,412 | $7 |
| Long return visit (40+ min) | 21 | $3,518 | $126 |
| New patient visit (60+ min) | 22 | $3,198 | $145 |
| Critical care, each additional 30 minutes | 17 | $2,143 | $97 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 15 | $1,289 | $76 |
| Insertion of artery tube for blood sampling or infusion through skin | 11 | $470 | $39 |
2018: 5 services
| Critical care, first 30-74 minutes | 329 | $143,766 | $190 |
| Long return visit (40+ min) | 72 | $11,697 | $97 |
| New patient visit (60+ min) | 20 | $2,974 | $149 |
| Long return visit (40+ min) | 11 | $1,692 | $130 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 129 | $1,215 | $7 |
2017: 4 services
| Critical care, first 30-74 minutes | 277 | $116,302 | $179 |
| Long return visit (40+ min) | 62 | $8,345 | $91 |
| Long return visit (40+ min) | 33 | $4,695 | $115 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 95 | $706 | $7 |
2016: 3 services
| Critical care, first 30-74 minutes | 105 | $43,766 | $191 |
| Long return visit (40+ min) | 22 | $3,608 | $129 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 14 | $774 | $55 |
2015: 1 service
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 14 | $797 | $57 |
2014: 6 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 122 | $7,140 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,891 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,321 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,737 | $64 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $79 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $42 | $3 |
2013: 11 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 301 | $17,149 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,972 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $6,287 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $4,965 | $89 |
| Hospital discharge day management, 30 minutes or less | 32 | $2,177 | $64 |
| Long return visit (40+ min) | 11 | $1,721 | $96 |
| Ultrasound of heart, follow-up | 23 | $489 | $20 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 28 | $169 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 36 | $113 | $3 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $102 | $9 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 12 | $95 | $6 |
Medicaid work
$35,782 in 2024
Medicaid paid $35,782 for 232 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 215 | $33,358 |
| Long return visit (40+ min) | 17 | $2,424 |
| 2024 | 232 | 2 | 18 | $35,782 |
| 2023 | 151 | 1 | 17 | $24,681 |
| 2022 | 142 | 2 | 15 | $18,638 |
| 2021 | 30 | 1 | 12 | $2,767 |
| 2020 | 219 | 2 | 118 | $9,958 |
| 2019 | 672 | 3 | 135 | $10,179 |
| 2018 | 125 | 2 | 77 | $3,086 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 151 | $24,681 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 103 | $15,050 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 39 | $3,589 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 30 | $2,767 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 80 | $9,299 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 139 | $659 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 64 | $6,592 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 581 | $2,560 |
| Long return visit (40+ min) | 27 | $1,027 |
2018
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 20 | $2,668 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 105 | $418 |
Drugs they prescribed that Part D paid
$2,565,315
Pharmacies billed $2,565,315 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 415) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
208 generic and 207 brand-name prescriptions · $2,565,315 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Opsumit | 86 | $1,068,062 | $12,419 |
| Uptravi | 32 | $730,267 | $22,821 |
| Winrevair | 17 | $234,344 | $13,785 |
| Orenitram Er | 27 | $137,299 | $5,085 |
| Ambrisentan | 32 | $101,050 | $3,158 |
See all 12 drugs
| Opsumit | 86 | $1,068,062 | $12,419 |
| Uptravi | 32 | $730,267 | $22,821 |
| Winrevair | 17 | $234,344 | $13,785 |
| Orenitram Er | 27 | $137,299 | $5,085 |
| Ambrisentan | 32 | $101,050 | $3,158 |
| Adcirca | 12 | $48,663 | $4,055 |
| Tadalafil | 68 | $43,963 | $647 |
| Ozempic | 12 | $11,311 | $943 |
| Sildenafil Citrate | 16 | $5,181 | $324 |
| Spironolactone | 24 | $404 | $17 |
| Torsemide | 14 | $250 | $18 |
| Furosemide | 14 | $101 | $7 |
Year by year
| 2024 | 415 | 33 | 0% (0) | 50% | $2,565,315 |
| 2023 | 166 | 25 | 0% (0) | None | $931,093 |
| 2022 | 148 | 27 | 0% (0) | 48% | $1,590,441 |
| 2021 | 650 | 45 | 0% (0) | 49% | $5,802,292 |
| 2020 | 701 | 49 | 0% (0) | 48% | $4,653,995 |
| 2019 | 651 | 50 | 0% (0) | 52% | $4,323,510 |
| 2018 | 517 | 57 | 0% (0) | 61% | $2,594,275 |
| 2017 | 577 | 53 | 0% (0) | 57% | $1,757,395 |
| 2016 | 152 | 30 | None | 38% | $185,759 |
| 2015 | 36 | 15 | None | 44% | $87,538 |
| 2014 | 370 | 54 | None | 40% | $435,690 |
| 2013 | 551 | 77 | None | 35% | $325,119 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Uptravi | 15 | $348,870 | $23,258 |
| Opsumit | 24 | $313,097 | $13,046 |
| Tadalafil | 37 | $125,698 | $3,397 |
| Ambrisentan | 21 | $69,150 | $3,293 |
| Spironolactone | 12 | $586 | $49 |
2022: 3 drugs
| Uptravi | 39 | $698,588 | $17,913 |
| Orenitram Er | 14 | $570,132 | $40,724 |
| Tadalafil | 55 | $69,403 | $1,262 |
2021: 9 drugs
| Uptravi | 114 | $2,232,259 | $19,581 |
| Orenitram Er | 46 | $1,393,193 | $30,287 |
| Opsumit | 75 | $867,835 | $11,571 |
| Adempas | 55 | $675,388 | $12,280 |
| Tadalafil | 201 | $272,546 | $1,356 |
| Ambrisentan | 41 | $221,647 | $5,406 |
| Adcirca | 14 | $69,997 | $5,000 |
| Alyq | 16 | $27,093 | $1,693 |
| Torsemide | 22 | $762 | $35 |
2020: 11 drugs
| Uptravi | 90 | $1,812,221 | $20,136 |
| Opsumit | 82 | $886,418 | $10,810 |
| Orenitram Er | 48 | $732,065 | $15,251 |
| Adempas | 50 | $564,053 | $11,281 |
| Tadalafil | 192 | $214,971 | $1,120 |
| Letairis | 15 | $152,148 | $10,143 |
| Ambrisentan | 34 | $128,104 | $3,768 |
| Adcirca | 25 | $109,101 | $4,364 |
| Alyq | 51 | $45,918 | $900 |
| Torsemide | 35 | $1,189 | $34 |
| Furosemide | 17 | $135 | $8 |
2019: 12 drugs
| Uptravi | 72 | $1,316,356 | $18,283 |
| Opsumit | 85 | $860,354 | $10,122 |
| Orenitram Er | 33 | $589,829 | $17,874 |
| Adempas | 36 | $386,692 | $10,741 |
| Tadalafil | 149 | $346,998 | $2,329 |
| Letairis | 34 | $341,830 | $10,054 |
| Adcirca | 67 | $257,863 | $3,849 |
| Ambrisentan | 22 | $102,920 | $4,678 |
| Alyq | 24 | $61,849 | $2,577 |
| Sildenafil Citrate | 19 | $52,528 | $2,765 |
| Torsemide | 35 | $1,574 | $45 |
| Amlodipine Besylate | 12 | $57 | $5 |
2018: 10 drugs
| Uptravi | 33 | $670,211 | $20,309 |
| Adcirca | 140 | $580,868 | $4,149 |
| Letairis | 57 | $557,592 | $9,782 |
| Opsumit | 47 | $437,666 | $9,312 |
| Adempas | 14 | $138,995 | $9,928 |
| Tadalafil | 39 | $125,813 | $3,226 |
| Sildenafil | 11 | $2,299 | $209 |
| Torsemide | 60 | $1,927 | $32 |
| Spironolactone | 20 | $195 | $10 |
| Lisinopril | 14 | $90 | $6 |
2017: 12 drugs
| Adcirca | 181 | $702,797 | $3,883 |
| Letairis | 61 | $567,684 | $9,306 |
| Opsumit | 26 | $260,661 | $10,025 |
| Torsemide | 88 | $1,886 | $21 |
| Sildenafil | 21 | $1,194 | $57 |
| Bumetanide | 15 | $1,129 | $75 |
| Potassium Chloride | 23 | $1,048 | $46 |
| Spironolactone | 14 | $277 | $20 |
| Lisinopril | 14 | $185 | $13 |
| Amlodipine Besylate | 28 | $185 | $7 |
| Furosemide | 20 | $148 | $7 |
| Carvedilol | 14 | $84 | $6 |
2016: 4 drugs
| Adcirca | 29 | $95,108 | $3,280 |
| Sildenafil | 14 | $2,475 | $177 |
| Torsemide | 22 | $511 | $23 |
| Amlodipine Besylate | 11 | $39 | $4 |
2015: 1 drug
| Clopidogrel | 12 | $71 | $6 |
2014: 12 drugs
| Letairis | 31 | $223,395 | $7,206 |
| Adcirca | 92 | $196,108 | $2,132 |
| Sildenafil | 26 | $8,086 | $311 |
| Metoprolol | 17 | $1,357 | $80 |
| Clopidogrel | 25 | $470 | $19 |
| Atorvastatin | 12 | $308 | $26 |
| Spironolactone | 20 | $233 | $12 |
| Torsemide | 12 | $166 | $14 |
| Carvedilol | 12 | $95 | $8 |
| Furosemide | 11 | $74 | $7 |
| Lisinopril | 16 | $71 | $4 |
| Amlodipine Besylate | 11 | $33 | $3 |
2013: 14 drugs
| Letairis | 28 | $188,045 | $6,716 |
| Adcirca | 46 | $58,548 | $1,273 |
| Sildenafil | 11 | $16,216 | $1,474 |
| Crestor | 17 | $2,940 | $173 |
| Clopidogrel | 32 | $2,264 | $71 |
| Metoprolol | 35 | $2,260 | $65 |
| Atorvastatin | 29 | $1,071 | $37 |
| Torsemide | 18 | $693 | $39 |
| Spironolactone | 39 | $370 | $9 |
| Bumetanide | 12 | $297 | $25 |
| Furosemide | 50 | $279 | $6 |
| Losartan | 22 | $237 | $11 |
| Digox | 29 | $181 | $6 |
| Lisinopril | 13 | $107 | $8 |
Money from drug and device companies
$16,824 in 2025
| 2025 | 9 | 32 | $12,000 | $16,824 |
| 2024 | 11 | 30 | $10,363 | $14,487 |
| 2023 | 7 | 10 | $2,830 | $3,797 |
| 2022 | 4 | 8 | None | $756 |
| 2021 | 2 | 2 | None | $128 |
| 2020 | 2 | 4 | None | $263 |
| 2019 | 1 | 2 | None | $27 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Cardiomems | $14,238 | 17 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $1,500 | 1 payment
|
| Merck Sharp & Dohme | Winrevair | $432 | 6 payments
|
| United Therapeutics | None | $209 | 2 payments
|
| Abiomed | None | $135 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Adempas | $127 | 1 payment
|
See all 32 published payments
| Abbott Laboratories | Consulting · 2025-12-24 | Thoratec Heartmate 3 Lvas Implant Kit | $2,700 |
| Abbott Laboratories | Consulting · 2025-12-24 | Thoratec Heartmate 3 Lvas Implant Kit | $1,013 |
| Abbott Laboratories | Meals · 2025-12-14 | Thoratec Heartmate 3 Lvas Implant Kit | $25 |
| Abbott Laboratories | Meals · 2025-10-31 | Mediguide | $164 |
| Merck Sharp & Dohme | Meals · 2025-08-21 | Winrevair | $115 |
| Abbott Laboratories | Travel · 2025-06-18 | Cardiomems | $366 |
| Abbott Laboratories | Consulting · 2025-06-17 | 2nd Gen Centrimag Primary Console | $1,350 |
| Abbott Laboratories | Consulting · 2025-06-17 | 2nd Gen Centrimag Primary Console | $675 |
| Merck Sharp & Dohme | Meals · 2025-06-12 | None | $81 |
| Abbott Laboratories | Consulting · 2025-06-05 | Cardiomems | $3,375 |
| Abbott Laboratories | Consulting · 2025-06-05 | Cardiomems | $1,350 |
| Abbott Laboratories | Consulting · 2025-06-05 | Cardiomems | $38 |
| Abbott Laboratories | Travel · 2025-06-05 | Cardiomems | $1,856 |
| Abbott Laboratories | Travel · 2025-06-05 | Cardiomems | $45 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Honoraria · 2025-05-21 | Lifevest | $1,500 |
| Merck Sharp & Dohme | Meals · 2025-05-18 | None | $56 |
| AngioDynamics | Meals · 2025-05-09 | Alphavac | $17 |
| Merck Sharp & Dohme | Meals · 2025-04-30 | None | $101 |
| Merck Sharp & Dohme | Meals · 2025-04-29 | None | $35 |
| Abbott Laboratories | Meals · 2025-04-29 | Thoratec Heartmate 3 Lvas Implant Kit | $130 |
| Abbott Laboratories | Travel · 2025-04-29 | Thoratec Heartmate 3 Lvas Implant Kit | $185 |
| Abbott Laboratories | Travel · 2025-04-29 | Thoratec Heartmate 3 Lvas Implant Kit | $185 |
| Abbott Laboratories | Travel · 2025-04-29 | Thoratec Heartmate 3 Lvas Implant Kit | $9 |
| United Therapeutics | Meals · 2025-04-29 | None | $61 |
| Actelion Pharmaceuticals US | Meals · 2025-04-28 | None | $118 |
| Merck Sharp & Dohme | Meals · 2025-03-30 | None | $44 |
| Sandoz | Meals · 2025-03-21 | Treprostinil | $23 |
| Abiomed | Meals · 2025-02-27 | None | $135 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-26 | Adempas | $127 |
| Abbott Laboratories | Travel · 2025-02-26 | Thoratec Heartmate 3 Lvas Implant Kit | $772 |
| United Therapeutics | Meals · 2025-02-20 | None | $148 |
| Sandoz | Meals · 2025-01-22 | Treprostinil | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $14,487
| Abbott Laboratories | Freestyle Libre Pro | $9,192 | 15 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $2,000 | 1 payment
|
| Pfizer | None | $1,794 | 4 payments
|
| Abiomed | Impella | $742 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $275 | 2 payments
|
| Impulse Dynamics (USA) | Optimizer | $150 | 1 payment
|
| United Therapeutics | None | $142 | 1 payment
|
| Johnson & Johnson Health Care Systems | Uptravi | $108 | 1 payment
|
| Ethicon US | Monocryl | $39 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $29 | 1 payment
|
| Medtronic | Invos | $15 | 1 payment
|
2023: $3,797
| Bayer Healthcare Pharmaceuticals | Adempas | $1,830 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $1,000 | 1 payment
|
| Abbott Laboratories | Cardiomems | $264 | 2 payments
|
| Actelion Pharmaceuticals US | Uptravi | $223 | 2 payments
|
| Merck Sharp & Dohme | None | $221 | 2 payments
|
| Abiomed | Impella | $147 | 1 payment
|
| Getinge USA Sales | Cardiohelp | $112 | 1 payment
|
2022: $756
| Actelion Pharmaceuticals US | Uptravi | $499 | 4 payments
|
| Merck Sharp & Dohme | None | $109 | 1 payment
|
| United Therapeutics | Tyvaso | $87 | 1 payment
|
| Abiomed | Impella | $60 | 2 payments
|
2021: $128
| Actelion Pharmaceuticals US | Uptravi | $100 | 1 payment
|
| Amgen | Repatha | $28 | 1 payment
|
2020: $263
| Boston Scientific | Crossboss | $182 | 1 payment
|
| Amgen | Repatha | $81 | 3 payments
|
2019: $27
| Cook Medical | None | $27 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| BeiGene, Ltd. · A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for Covid 19 Infection and Pulmonary Distress · 2020 | Their institution | $105,235 |
| Merck Sharp & Dohme LLC · A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Compare the Efficacy and Safety of Sotatercept Ace-011 Versus Placebo When Added To Standard of Care for the Treatment of Pulmonary Arterial Hypertension Pah · 2022 | Their institution | $70,467 |
| PFIZER INC. · A Phase 1 Randomized Doubleblind Placebocontrolled Study To Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of Pf07868489 in Healthy Adult Participants and Repeat Doses in Participants With Pulmonary Arterial Hypertension · 2025 | Their institution | $62,847 |
| BeiGene, Ltd. · Treatment of Patients Hospitalized for Covid-19 Infection and Pulmonary Distress With Zanubrutinib · 2020 | Their institution | $30,200 |
| Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah Mk-7962-038 · 2025 | Their institution | $23,256 |
| Merck Sharp & Dohme LLC · A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Compare the Efficacy and Safety of Sotatercept Ace-011 Versus Placebo When Added To Standard of Care for the Treatment of Pulmonary Arterial Hypertension Pah · 2023 | Their institution | $18,357 |
| BeiGene, Ltd. · A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for Covid-19 Infection and Pulmonary Distress · 2021 | Their institution | $17,525 |
| Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah · 2025 | Their institution | $17,154 |
| Merck Sharp & Dohme Corporation · A Phase 2,3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study To Evaluate the Efficacy and Safety of Mk-5475 in Adults With Pulmonary Arterial Hypertension. · 2021 | Their institution | $16,014 |
| United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2019 | Their institution | $10,923 |
| BeiGene, Ltd. · A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for Covid-19 Infection and Pulmonary Distress · 2022 | Their institution | $10,725 |
| United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2020 | Their institution | $8,836 |
| Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah · 2022 | Their institution | $7,880 |
| Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah · 2024 | Their institution | $7,101 |
| United Therapeutics Corporation · A Multicenter Randomized Double-Blinded Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2020 | Their institution | $5,384 |
| United Therapeutics Corporation · A Multicenter Randomized Double-Blinded Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2019 | Their institution | $4,995 |
| Merck Sharp & Dohme LLC · An Open-Label Long-Term Follow-Up Study To Evaluate the Effects of Sotatercept When Added To Background Pulmonary Arterial Hypertension Pah Therapy for the Treatment of Pah · 2023 | Their institution | $4,342 |
| United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due To Parenchymal Lung Disease · 2021 | Their institution | $4,070 |
| Actelion Pharmaceuticals, Ltd · Opus - Ac-055-503 · 2019 | Their institution | $500 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1538127717
- Licence
- CA A99520, DC MD043864, MD D0061892California A99520: Current · expires 2028-11-30
- Trained
- Northwestern University Feinberg Medical School, 2001 · 25 years ago
- Group
- University of California San Francisco · Regents of the University of California
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- DC 36932200, MD 408398900
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RA0001X (207RA0001X); Cardiology (207RC0000X); Federal specialty code 2086S0102X (2086S0102X)
- Mailing address
- 910 Presidio Ave, Apt 3, San Francisco, CA, 94115
- NPI first listed
- 2006-05-04
- NPI last updated
- 2021-10-14
- NPI record certified
- 2021-10-14
This is when the NPI record was last certified, not a medical board exam.